Basavaraju G. Sanganahalli, PhD
Assistant Professor of Radiology and Biomedical ImagingCards
About
Titles
Assistant Professor of Radiology and Biomedical Imaging
Director, Small Animal MRI Core, Magnetic Resonance Research Center
Biography
I am a translational neuroscientist whose research integrates neurophysiology with advanced multimodal MRI to understand the biophysics of brain function and dysfunction. My expertise in combining fMRI, MRS, and DTI with electrophysiology and behavioral paradigms provides a unique framework to bridge neuronal activity, metabolism, and vascular responses across spatial and temporal scales. This integrative approach allows me to probe fundamental mechanisms of brain network organization and their disruption in disease.
My work focuses on uncovering the mechanistic basis of brain dysfunction and translating these findings into clinically relevant biomarkers. I apply this framework to study a broad spectrum of conditions, including healthy aging, Alzheimer’s disease, epilepsy, early life stress, schizophrenia, stroke, mild traumatic brain injury, and spinal cord injury. Through these studies, I aim to identify quantifiable, non-invasive biomarkers that enable early diagnosis, track disease progression, and assess therapeutic efficacy.
As Director of the Small Animal MRI Core, I lead the development of cutting-edge imaging methodologies and collaborative translational neuroscience programs. My long-term goal is to bridge basic and clinical research by advancing the next generation of imaging biomarkers that precisely capture neural circuit dynamics underlying brain health and disease.
Appointments
Radiology & Biomedical Imaging
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- PhD
- National Institute of Mental Health and Neuroscience, Neuroscience (2004)
- MPhil
- National Institute of Mental health and Neurosciences, Biophysics (1997)
- MS
- Bangalore University, Physics (1995)
Research
Publications
2025
Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP‐Ribose) Polymerase Inhibitor Veliparib
Koehler R, Bedirian K, Chen M, Shi Y, Cao S, Avery B, Karuppagounder S, Akhter K, Bibic A, Dawson V, Dawson T, Diniz M, Lamb J, Nagarkatti K, Chauhan A, Aronowski J, McCullough L, de Morais A, Jin X, Ayata C, Kumskova M, Patel R, Chauhan A, Leira E, Kamat P, Khan M, Dhandapani K, Hess D, Boisserand L, Sanganahalli B, Sansing L, Lyden P, Lyden P, Lamb J, Nagarkatti K, Bedirian K, Chen M, Diniz M, Hess D, Kamat P, Khan M, Dhandapani K, Arbab A, Siddiqui S, Smith C, Nisar M, Leira E, Chauhan A, Dhanesha N, Patel R, Kumskova M, Thedens D, Wang K, Ayata C, de Morais A, Imai T, Qin T, Jin X, Erdogan T, Yu L, Mandeville J, Kimberly W, Whittier J, Lo E, Arai K, Van Leyen K, Sansing L, Hyder F, Mihailovic J, Sanganahalli B, Diaz‐Perez S, Velazquez S, Beatty H, Johnson C, Herman A, Immakavar E, Koehler R, Dawson T, Dawson V, Shi Y, Cao S, Avery B, Lannon S, Bibic A, Akhter K, Karuppagounder S, Aronowski J, McCullough L, Obertas L, Goh A, Huang S. Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP‐Ribose) Polymerase Inhibitor Veliparib. Journal Of The American Heart Association 2025, 14: e040914. PMID: 40996065, PMCID: PMC12684482, DOI: 10.1161/jaha.124.040914.Peer-Reviewed Original ResearchConceptsSpontaneously Hypertensive RatsAged miceAged animal modelsVeliparib treatmentPARP inhibitor veliparibYoung miceHypertensive ratsBenefit of PARP inhibitorsIntravenous injectionObese miceIschemic strokeRisk factor subgroupsAnimal models of strokeCorner testGrid-walking testModels of strokeIndependent of sexPARP inhibitorsFocal ischemic strokeVeliparibDays of recoveryPrimary outcomeFunctional outcomesLesion volumeSecondary outcomesFingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network
Boisserand L, Herman A, Sanganahalli B, Mihailovic J, Beatty H, Johnson C, Diaz S, DeLong J, Velazquez S, Grutzendler J, Dela Cruz C, Zhou J, Sheth K, Matouk C, Zhan S, Morais A, Imai T, Chauhan A, Patel R, Kumskova M, Shi Y, Avery B, Lamb J, Nagarkatti K, Khan M, Kamat P, Dhandapani K, McCullough L, Aronowski J, Hess D, Koehler R, Lyden P, Leira E, Chauhan A, Ayata C, Chen M, Diniz M, Hyder F, Sansing L, Investigators O. Fingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network. Stroke 2025, 56: 3280-3293. PMID: 40899256, DOI: 10.1161/strokeaha.125.050903.Peer-Reviewed Original ResearchSphingosine-1-phosphate receptorsComorbidity modelFunctional outcomesLesion sizeDay 7Therapeutic potentialEffects of fingolimodSecondary lymphoid organsYoung healthy miceClinically relevant modelMiddle cerebral artery occlusionPrimary functional outcomeBrain morphometrySpontaneously Hypertensive RatsCerebral artery occlusionCorner testSphingosine-1-PhosphateMagnetic resonance imagingHigh-fat dietFoot-fault testFingolimod effectsImmunomodulatory drugsLess atrophyHealthy miceFingolimodMapping of neurovascular and neurometabolic couplings by multimodal optical imaging
Herman P, Sanggaard S, James S, Akif A, Mishra S, Sanganahalli B, Verhagen J, Blumenfeld H, Hyder F. Mapping of neurovascular and neurometabolic couplings by multimodal optical imaging. Cerebral Cortex 2025, 35: bhaf165. PMID: 40624899, DOI: 10.1093/cercor/bhaf165.Peer-Reviewed Original ResearchConceptsCerebral blood volumeNeuronal activityNeurometabolic couplingAlterations of neuronal activityNeurovascular couplingImaging of metabolic activityCerebral blood volume changesBolus injectionGlucose uptakeMultimodal optical imagingBlood volumeCalcium indicatorNear-infrared spectroscopyOptical imagingSimultaneous imagingBlood volume changesNear-infrared spectroscopy recordingsTraumatic brain injuryBrain injuryMultiplexed optical imagingGlucose analogMetabolic activityGECIsOptical systemCa2Multicenter SPAN Trial of Fasudil in Ischemic Stroke
Imai T, de Morais A, Jin X, Qin T, Lamb J, Nagarkatti K, Chen M, Boisserand L, Patel R, Kumskova M, Chauhan A, Dhandapani K, Khan M, Kamat P, Shi Y, Cao S, Sanganahalli B, Mandeville J, Lyden P, Hess D, Leira E, Chauhan A, Aronowski J, McCullough L, Koehler R, Sansing L, Diniz M, Ayata C, Investigators O. Multicenter SPAN Trial of Fasudil in Ischemic Stroke. Stroke 2025, 56: 2306-2317. PMID: 40421536, PMCID: PMC12407252, DOI: 10.1161/strokeaha.125.050977.Peer-Reviewed Original ResearchSpontaneously Hypertensive RatsRho-associated kinase inhibitorHypertensive ratsAged miceActive treatment armsIschemic strokeModified intention-to-treat cohortKinase inhibitorsPrimary outcome end pointsIntention-to-treat cohortTest performanceEfficacy of fasudilPer-protocol populationOutcome end pointsMiddle cerebral artery occlusion modelHealthy young miceDiet-induced obese miceRodent modelsTrials NetworkTherapeutic profileFocal ischemic strokeTreatment armsYoung miceVehicle armSecondary outcomesUric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial
Patel R, Kumskova M, Kodali H, Budnik I, Kuznetsov V, Jain A, Jha A, Thedens D, Dhanesha N, Sutariya B, Nagarkatti K, Lamb J, Kamat P, Shi Y, Avery B, Imai T, Jin X, Chauhan A, Boisserand L, Khan M, Dhandapani K, Sanganahalli B, Sansing L, Hess D, Koehler R, McCullough L, Aronowski J, Ayata C, Diniz M, Lyden P, Planas A, Chamorro A, Chauhan A, Leira E, Investigators O. Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. Stroke 2025, 56: 965-973. PMID: 40091742, PMCID: PMC11932773, DOI: 10.1161/strokeaha.124.048748.Peer-Reviewed Original ResearchConceptsUA-treated animalsPrimary functional outcomeFunctional outcomesMiddle cerebral artery filament occlusionModified intention-to-treat populationIntention-to-treat populationUric acidHuman clinical trialsImprove functional outcomesStudy drugIntravenous salineEffects of UARelevant to patientsClinical trialsPrimary outcomeSaline controlsSecondary outcomesPreclinical trialsDay 2Survival rateDay 7Filament occlusionGroups of animalsComorbiditiesDiverse comorbidities
2024
Transient impairment in microglial function causes sex-specific deficits in synaptic maturity and hippocampal function in mice exposed to early adversity
Ahmed S, Polis B, Jamwal S, Sanganahalli B, MacDowell Kaswan Z, Islam R, Kim D, Bowers C, Giuliano L, Biederer T, Hyder F, Kaffman A. Transient impairment in microglial function causes sex-specific deficits in synaptic maturity and hippocampal function in mice exposed to early adversity. Brain Behavior And Immunity 2024, 122: 95-109. PMID: 39134183, PMCID: PMC11402597, DOI: 10.1016/j.bbi.2024.08.010.Peer-Reviewed Original ResearchEarly-life adversityModel of early-life adversityContextual fear conditioningLimited beddingFear conditioningSynaptic engulfmentLB miceSynaptic pruningSex-specific deficitsHippocampus of maleSex-specific effectsHippocampal deficitsAdolescent miceHippocampal functionEarly adversityChemogenetic activationSynaptic connectionsBehavioral aberrationsPotential compensatory mechanismsSynaptic abnormalitiesHippocampusAblation of microgliaRodent hippocampusDeficitsWeeks of lifemTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner
Sanganahalli B, Mihailovic J, Vekaria H, Coman D, Yackzan A, Flemister A, Aware C, Wenger K, Hubbard W, Sullivan P, Hyder F, Lin A. mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer’s disease in an APOE genotype-dependent manner. Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism 2024, 44: 1745-1758. PMID: 38879800, PMCID: PMC11494852, DOI: 10.1177/0271678x241261942.Peer-Reviewed Original ResearchResponse to rapamycinE3FAD miceMitochondrial functionAlzheimer's diseaseMammalian target of rapamycinAD genetic risk factorsApolipoprotein E4Neuronal mitochondrial functionMitochondrial oxidative metabolismE4FAD miceHuman APOE4 geneTCA cycle rateGenetic risk factorsGenotype-dependent mannerE3FADTarget of rapamycinAPOE4 geneAPOE3 alleleGlutamate-glutamine cycleAPOE4 carriersBioenergetic measurementsE4FADMetabolic functionsAPOE genotypeMammalian target of rapamycin inhibitionVEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model
Boisserand L, Geraldo L, Bouchart J, Kamouh M, Lee S, Sanganahalli B, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez S, Singhabahu R, Robinson M, Askenase M, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing L, Benveniste H, Hyder F, Thomas J. VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model. Journal Of Experimental Medicine 2024, 221: e20221983. PMID: 38442272, PMCID: PMC10913814, DOI: 10.1084/jem.20221983.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor-CDeep cervical lymph nodesCentral nervous systemEffect of vascular endothelial growth factor-CMeningeal lymphatic vesselsAmeliorated motor performanceCervical lymph nodesIschemic strokeVEGF-C overexpressionIncreased BDNF signalingAcute ischemic strokeBrain cellsIncreased CSF drainageIschemic stroke outcomesModel of ischemic strokeMouse model of ischemic strokeImmune surveillanceCSF drainageLymph nodesFluid drainageNucleus RNA sequencingLymphatic growthLymphatic drainageMouse modelBDNF signaling
2023
Cross-hemicord spinal fiber reorganization associates with cortical sensory and motor network expansion in the rat model of hemicontusion cervical spinal cord injury
Mihailovic J, Sanganahalli B, Hyder F, Chitturi J, Elkabes S, Heary R, Kannurpatti S. Cross-hemicord spinal fiber reorganization associates with cortical sensory and motor network expansion in the rat model of hemicontusion cervical spinal cord injury. Neuroscience Letters 2023, 820: 137607. PMID: 38141752, PMCID: PMC10797561, DOI: 10.1016/j.neulet.2023.137607.Peer-Reviewed Original ResearchConceptsSpinal cord injuryCervical spinal cord injuryDiffusion tensor imagingCord injurySpinal cordCervical spinal cordState functional connectivitySpinal cord samplesSpinal cord diffusion tensor imagingMagnetic resonance imagingBrain functional MRIInjury epicenterSpinal reorganizationPost-SCINeuroplastic changesCord samplesCortical sensoryRat modelTraumatic injuryMD changeMotor networkNervous systemResonance imagingSingle-subject levelFunctional MRIFluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy
Arul M, Alahmadi I, Turro D, Ruikar A, Abdulmalik S, Williams J, Sanganahalli B, Liang B, Verma R, Kumbar S. Fluorescent liposomal nanocarriers for targeted drug delivery in ischemic stroke therapy. Biomaterials Science 2023, 11: 7856-7866. PMID: 37902365, PMCID: PMC10697427, DOI: 10.1039/d3bm00951c.Peer-Reviewed Original ResearchConceptsSurgical clot removalPEGylated liposomal formulationPreclinical mouse modelsShorter treatment durationPurinergic receptor P2X4Reduced infarct volumeAcute CNS injuryCNS infiltrationLong-term disabilitySystemic deliveryTreatment optionsLiposomal formulationIschemic stroke therapyVulnerable brain regionsAdministered 4Clot removalInfarct volumeLow dosesTreatment durationMouse modelNeuroprotective therapiesCNS injuryLiposomal nanocarriersStroke therapyIschemic stroke